Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer
Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Immune checkpoint inhibitors (ICIs), including programmed cell death 1 (PD-1) antibody, programmed cell death ligand 1 (PD-L1) antibody, and cytotoxic T lymphocyte associated protein 4 (CTLA-4) antibody...
Guardado en:
Autores principales: | Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy, Chinese Society of Clinical Oncology, Expert Committee on Non-small Cell Lung Cancer |
---|---|
Formato: | article |
Lenguaje: | ZH |
Publicado: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/73efbbca7aad481c9495e49e699bda8c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Expert consensus on diagnosis, treatment and fertility management of young breast cancer patients
por: Committee of Diagnosis, Treatment, and Fertility Management of Chinese Young Breast Cancer Patients
Publicado: (2021) -
Chinese Expert Consensus on Iodine125 Seed Implantation for Recurrent Cervical Cancer in 2021
por: Ping Jiang, et al.
Publicado: (2021) -
A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors
por: Nagasaka M, et al.
Publicado: (2019) -
Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor types
por: Zhe Gong, et al.
Publicado: (2021) -
Targeting Tumor-Associated Macrophages in Cancer Immunotherapy
por: Amy J. Petty, et al.
Publicado: (2021)